Latest news with #4baseCare
Hindustan Times
01-07-2025
- Health
- Hindustan Times
Cardiologist shares most dangerous food habits that could silently increase your risk of heart attack: ‘Eat more fibre'
Cancer relapse is a complex mechanism and influenced by many factors. Tumour is heterogenous and constantly evolving. In an interview with HT Lifestyle, Dr Anjali Kulkarni, Vice President - RWE Strategy and Analytics and Oncologist at 4baseCare, explained, 'Some patients may have germline mutations (e.g., BRCA1/2) that increase not only risk of cancer but also risk of recurrence. In a few cases, there can be defects in genes that help repair DNA (e.g., TP53, ATM, CHEK2) can lead to relapse due to failure to correct genetic damage.'
Hindustan Times
01-07-2025
- Health
- Hindustan Times
Louis Vuitton turns India's iconic auto-rickshaw into luxury handbag; internet says ‘waiting for Chandni Chowk version'
Cancer relapse is a complex mechanism and influenced by many factors. Tumour is heterogenous and constantly evolving. In an interview with HT Lifestyle, Dr Anjali Kulkarni, Vice President - RWE Strategy and Analytics and Oncologist at 4baseCare, explained, 'Some patients may have germline mutations (e.g., BRCA1/2) that increase not only risk of cancer but also risk of recurrence. In a few cases, there can be defects in genes that help repair DNA (e.g., TP53, ATM, CHEK2) can lead to relapse due to failure to correct genetic damage.'
Time of India
16-05-2025
- Health
- Time of India
4baseCare launches genomics lab
Bengaluru: Oncology company 4baseCare has launched a genomics laboratory and the Global Cancer Diversity Atlas (GCDA) in Mahadevapura, Bengaluru. According to the company, the genomics lab will offer testing services including gene panels, whole exome sequencing , and transcriptome analysis , aimed at helping oncologists tailor cancer treatment based on tumor genetics . The GCDA, also developed by the company, is designed to address gaps in cancer genomics data. The company states that it is built using real-world data from India and other regions across the Global South—including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. It is intended to support diagnostic development, research, and personalized cancer care .
The Hindu
15-05-2025
- Health
- The Hindu
Bengaluru company unveils cancer atlas mapping genomic diversity to bridge data gap
A private firm in Bengaluru unveiled a Global Cancer Diversity Atlas (GCDA) on May 14 with the aim of addressing the genomics data gap in cancer care. The atlas was launched by Infosys co-founder N. R. Narayan Murthy. The initiative is aimed at addressing a critical gap in global cancer research — the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, the GCDA designed by 4baseCare, a precision oncology company, is built on real-world data from India and the global South. While over 70% of cancer patients live in Asia, West Asia and Latin America, less than 10% of current cancer genomic data represents them. GCDA aims to bridge this disparity to ensure all populations are accurately represented in precision oncology. The company claims that GCDA is the most inclusive cancer genomics dataset, transforming how it develops diagnostics, conducts research, and delivers cancer care. By integrating region-specific genomic insights, GCDA empowers clinicians with tools for more accurate diagnosis and targeted treatments, helping to eliminate misdiagnoses and enhance outcomes for patients worldwide. Mr. Murthy also launched the company's genomics lab in Mahadevapura. The lab will offer advanced genomic testing solutions, including comprehensive gene panels, whole exome sequencing and transcriptome analysis.
Hans India
28-04-2025
- Health
- Hans India
AIIMS Jammu launches centre for advanced genomics, precision medicine to boost cancer care
Jammu: The All-India Institute of Medical Sciences (AIIMS) Jammu on Monday launched the Centre for Advanced Genomics and Precision Medicine to boost affordable, precision-driven cancer care with advanced Next Generation Sequencing (NGS) technology. The Centre, developed in collaboration with oncology company 4baseCare, is equipped with the Illumina NextSeq 2000 sequencing machine, offering comprehensive genomic profiling for cancer patients. The powerful technology enables clinicians to design highly personalised, targeted treatment plans tailored to each patient's unique molecular profile. AIIMS Jammu announced its collaboration with 4baseCare in January. 'For every patient we treat, we are treating a mother, a father, a sister, or a brother. This partnership is our promise to every family who walks through our doors that we will do everything in our power to bring them the care they deserve,' Prof (Dr) Shakti Kumar Gupta, Executive Director and CEO, AIIMS Jammu. 'By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimise ineffective treatments -- ultimately enhancing both patient outcomes and quality of life,' said Dr. Sudharshan Elangovan, Vice President – Global Operations at 4baseCare. Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India. Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers. The Centre will focus on targeted, biomarker-driven therapies, enabling personalised treatment plans to improve outcomes and quality of life of cancer patients. Using genomics the facility also aims to tackle rare diseases. And to boost healthier pregnancies, the centre will integrate cutting-edge genetic technologies such as Non-Invasive Prenatal Testing (NIPT), Preimplantation Genetic Screening (PGS), and Preimplantation Genetic Diagnosis (PGD).
